Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03029325 · ClinicalTrials.gov registry record

Molecular and Genetic Analysis of Lung Cancer

A clinical trial of Lung Cancer, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
15,000
Enrollment target
1
Study location

NCT03029325 is a study of Lung Cancer that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 15,000 participants, above the 899-participant average among 409 other Lung Cancer trials with a reported enrollment target (1569% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03029325, a study of Lung Cancer, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
15,000 participants
Enrollment target
1
Study location

Study Summary

Investigators use a genome-wide approach within a case-control design to identify SNPs that show evidence of association with lung cancer risk and survival.

Conditions Studied

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 15,000 participants
Start Date 1993-06
Est. Completion 2026-09

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT03029325

The ClinicalTrials.gov registry entry for NCT03029325 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 15,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 899-participant average among 409 other Lung Cancer trials with a reported enrollment target (1569% higher). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT03029325 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03029325 about?

NCT03029325 is a clinical study titled "Molecular and Genetic Analysis of Lung Cancer". Investigators use a genome-wide approach within a case-control design to identify SNPs that show evidence of association with lung cancer risk and survival.

What is the current status of trial NCT03029325?

This trial is currently recruiting. The enrollment target is 15,000 participants. The study started on 1993-06. Estimated completion is 2026-09.

What conditions does trial NCT03029325 study?

This clinical trial studies the following conditions: Lung Cancer.

Who is sponsoring clinical trial NCT03029325?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03029325 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.